Earnings Report 5.302 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.954 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.770 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a similar treatment, is giving back 2.5%. Medicare Selected Novo’s ...

While ODAC could still decide to back the drug at the meeting, the FDA isn't beholden to follow its experts' advice. It's shaping up to be a real blow to both Innovent and Lilly, which paid $200 ...

see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to ...

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"2024 was a pivotal and highly successful year for Lilly, and we expect to continue ... please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities ...

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to ...